Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Abstract: A method for preparing a large-size two-dimensional layered metal thiophosphate crystal includes the following steps: 1) weighing raw materials of indium spheres, phosphorous lumps and sulfur granules according to a predetermined amount and proportion, mixing them, and using iodine as a transport agent and potassium iodide as a molten salt; 2) adding the raw materials, the iodine and the potassium iodide to a reaction vessel together, and vacuum sealing it under a certain pressure, and then subjecting it to a high-temperature reaction; 3) taking out the products after the reaction, and washing the products to remove the residual iodine and potassium iodide and obtain large-size two-dimensional layered metal thiophosphate crystals. This method is simple and highly efficient.

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.

Abstract: A method for preparing a large-size two-dimensional layered metal thiophosphate crystal includes the following steps: 1) weighing raw materials of indium spheres, phosphorous lumps and sulfur granules according to a predetermined amount and proportion, mixing them, and using iodine as a transport agent and potassium iodide as a molten salt; 2) adding the raw materials, the iodine and the potassium iodide to a reaction vessel together, and vacuum sealing it under a certain pressure, and then subjecting it to a high-temperature reaction; 3) taking out the products after the reaction, and washing the products to remove the residual iodine and potassium iodide and obtain large-size two-dimensional layered metal thiophosphate crystals. This method is simple and highly efficient.

Abstract: Disclosed is a server node ID address recognition device, including: a first recognition module, arranged in a cabinet and provided with a light entrance hole and a plurality of light exit holes; a plurality of case vertical plates arranged in the cabinet, each including a light exit hole and a plurality of light entrance holes, and a number and positions of the light entrance holes in each case vertical plate are configured to be associated with an ID address; and a second recognition module arranged on a server, including a light source, the second recognition module is provided with a light exit hole and a plurality of light entrance holes corresponding to the first recognition module.

Abstract: Disclosed is a server node ID address recognition device, including: a first recognition module, arranged in a cabinet and provided with a light entrance hole and a plurality of light exit holes; a plurality of case vertical plates arranged in the cabinet, each including a light exit hole and a plurality of light entrance holes, and a number and positions of the light entrance holes in each case vertical plate are configured to be associated with an ID address; and a second recognition module arranged on a server, including a light source, the second recognition module is provided with a light exit hole and a plurality of light entrance holes corresponding to the first recognition module.

Abstract: The present application relates to novel substituted imidazo[4,5-c]cinnolin-2-one compounds and pharmaceutically acceptable salts thereof, which selectively modulate ataxia telangiectasia mutated (“ATM”) kinase. The present application also relates to pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and to the use of the compounds and salts thereof in the treatment of ATM-associated diseases or conditions, including cancers.

Abstract: The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.